Last updated: February 14, 2026
Overview:
NDC 62584-0813 is a biosimilar product of rituximab, marketed under the brand name Ruxience. It is a monoclonal antibody indicated for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis in specific populations. As a biosimilar, it competes directly with the reference product, Rituxan (rituximab), offering potential cost savings and expanded access.
Market Size and Dynamics:
The global rituximab market was valued at approximately $8.7 billion in 2022, with biosimilars contributing an increasing share as patent expirations approach or occur. The U.S. market accounted for roughly 60% of this volume, driven by high prevalence of non-Hodgkin’s lymphoma and autoimmune diseases.
Key drivers:
- Expiring patents for the reference drug (Rituxan, originally patent expired in 2018 in the U.S.)
- Incentives for biosimilar adoption due to cost-effectiveness
- Regulatory pathways simplified through FDA approval processes such as abbreviated biologics license applications (BLAs)
Market Penetration Factors:
Regulatory acceptance: Ruxience received FDA approval in 2019. Adoption is influenced by physician trust, payer policies, and hospital formularies.
Reimbursement policies: Center for Medicare & Medicaid Services (CMS) encourages biosimilar use, promoting coverage and favorable reimbursement rates.
Physician and patient acceptance: Initially slow, but increasing with real-world evidence and cost savings.
Competitive landscape:
- Established biosimilars: Truxima (approved in 2018)
- Other entrants: Pfizer’s Ruxience, Celltrion’s Truxima, Sandoz’s Riximyo (Canada), among others.
Pricing Trends and Projections:
Current U.S. list price for Ruxience ranges from $4,500 to $6,000 per dose, significantly lower than Rituxan’s $9,000 to $10,000.
Price declines are expected as generic and biosimilar competition intensifies:
- Short-term (next 1-2 years): Prices likely to stay stable or decrease moderately (~10-15%).
- Mid-term (3-5 years): Additional decline possible, up to 30% compared to initial biosimilar launch prices, influenced by entry of new biosimilars and payer negotiations.
- Long-term (beyond 5 years): Prices could stabilize at 50-60% of reference drug levels as market saturation occurs, with additional cost-saving incentives.
Forecasts for 2025 and 2030:
| Year |
Expected Average Price per Dose |
Market Share of Biosimilar |
Total Revenue Potential |
| 2023 |
$4,700 – $5,200 |
70% |
$1.2 billion |
| 2025 |
$4,200 – $4,800 |
80% |
$1.5 billion |
| 2030 |
$3,500 – $4,000 |
90% |
$2 billion |
Factors Impacting Projections:
- Entry of new biosimilar competitors.
- Changes in FDA or payor policies favoring biosimilar adoption.
- Patent litigations or biosimilar exclusivity periods.
- Clinical evidence influencing physician prescribing patterns.
Summarized Risks and Opportunities:
- Price erosion risk exists with increasing supply and competition.
- Cost advantages could lead to broader indications and off-label uses, expanding the market.
- Unexpected regulatory or reimbursement hurdles could slow penetration, maintaining prices longer.
Key Takeaways
- NDC 62584-0813 (Ruxience) plays a substantial role in the biosimilar rituximab market, amplifying competition since its approval in 2019.
- Prices are currently 40-50% lower than the reference drug, with an expected gradual decline to 60-70% of reference brand pricing within five years.
- Market share is projected to reach 80-90% by 2030, driven by wider adoption and increasing payer pressure.
- Revenue growth depends on biosimilar entry timing, regulatory support, and success in changing prescribing habits.
FAQs
1. What factors could accelerate biosimilar price declines?
Increased competition, payer rebates, and regulatory policies favoring biosimilar substitution can lower prices more quickly. New biosimilars entering the market reduces market power of the incumbent biosimilar, further driving prices down.
2. How does biosimilar acceptance vary regionally?
Regulatory environments, reimbursement policies, and clinician acceptance vary. The U.S. has seen gradual adoption, while countries like Europe favor quicker uptake due to established biosimilar policies.
3. Are there legal or patent issues affecting NDC 62584-0813?
Patent litigations and exclusivity periods could influence market entry for other biosimilars, impacting prices and market share. So far, no major legal delays are publicly reported.
4. What are the major barriers to biosimilar market growth?
Physician mistrust, supply chain issues, or complex switching policies can slow adoption. Payer opposition or limited interchangeability designation may also limit substitution rates.
5. How do healthcare providers decide between biosimilars and reference biologics?
Cost savings, formulary preferences, and clinical evidence drive decisions. Increasing real-world data suggesting biosimilars are equally effective and safe support higher adoption rates.
References
- Evaluate Pharma, 2022 Market Reports.
- FDA Approvals (2019), Ruxience (NDC 62584-0813) details.
- IQVIA, 2022 Biologics Market Data.
- CMS Policy Documentation, 2022.
- Sander, T. et al., "Biosimilar Market Dynamics," J Pharmaceut Sci, 2022.
